Literature DB >> 27081720

siRNA Therapeutics for Primary Hyperoxaluria: A Beginning.

Dawn S Milliner1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27081720      PMCID： PMC4886951          DOI： 10.1038/mt.2016.50

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  14 in total

Review 1.  RNA Interference (RNAi)-Based Therapeutics: Delivering on the Promise?

Authors:  Maggie L Bobbin; John J Rossi
Journal:  Annu Rev Pharmacol Toxicol       Date:  2016       Impact factor: 13.820

Review 2.  Primary hyperoxaluria.

Authors:  Pierre Cochat; Gill Rumsby
Journal:  N Engl J Med       Date:  2013-08-15       Impact factor: 91.245

3.  Phenotype-Genotype Correlations and Estimated Carrier Frequencies of Primary Hyperoxaluria.

Authors:  Katharina Hopp; Andrea G Cogal; Eric J Bergstralh; Barbara M Seide; Julie B Olson; Alicia M Meek; John C Lieske; Dawn S Milliner; Peter C Harris
Journal:  J Am Soc Nephrol       Date:  2015-02-02       Impact factor: 10.121

4.  Transplantation outcomes in primary hyperoxaluria.

Authors:  E J Bergstralh; C G Monico; J C Lieske; R M Herges; C B Langman; B Hoppe; D S Milliner
Journal:  Am J Transplant       Date:  2010-09-17       Impact factor: 8.086

5.  Efficacy and safety of Oxalobacter formigenes to reduce urinary oxalate in primary hyperoxaluria.

Authors:  Bernd Hoppe; Jaap W Groothoff; Sally-Anne Hulton; Pierre Cochat; Patrick Niaudet; Markus J Kemper; George Deschênes; Robert Unwin; Dawn Milliner
Journal:  Nephrol Dial Transplant       Date:  2011-04-02       Impact factor: 5.992

6.  Oxalate quantification in hemodialysate to assess dialysis adequacy for primary hyperoxaluria.

Authors:  Xiaojing Tang; Nikolay V Voskoboev; Stacie L Wannarka; Julie B Olson; Dawn S Milliner; John C Lieske
Journal:  Am J Nephrol       Date:  2014-04-26       Impact factor: 3.754

7.  Mutations in HAO1 encoding glycolate oxidase cause isolated glycolic aciduria.

Authors:  Yaacov Frishberg; Avraham Zeharia; Roman Lyakhovetsky; Ruth Bargal; Ruth Belostotsky
Journal:  J Med Genet       Date:  2014-07-04       Impact factor: 6.318

Review 8.  The primary hyperoxalurias.

Authors:  Bernd Hoppe; Bodo B Beck; Dawn S Milliner
Journal:  Kidney Int       Date:  2009-02-18       Impact factor: 10.612

9.  Safety and efficacy of RNAi therapy for transthyretin amyloidosis.

Authors:  Teresa Coelho; David Adams; Ana Silva; Pierre Lozeron; Philip N Hawkins; Timothy Mant; Javier Perez; Joseph Chiesa; Steve Warrington; Elizabeth Tranter; Malathy Munisamy; Rick Falzone; Jamie Harrop; Jeffrey Cehelsky; Brian R Bettencourt; Mary Geissler; James S Butler; Alfica Sehgal; Rachel E Meyers; Qingmin Chen; Todd Borland; Renta M Hutabarat; Valerie A Clausen; Rene Alvarez; Kevin Fitzgerald; Christina Gamba-Vitalo; Saraswathy V Nochur; Akshay K Vaishnaw; Dinah W Y Sah; Jared A Gollob; Ole B Suhr
Journal:  N Engl J Med       Date:  2013-08-29       Impact factor: 91.245

10.  NALP3-mediated inflammation is a principal cause of progressive renal failure in oxalate nephropathy.

Authors:  Felix Knauf; John R Asplin; Ignacio Granja; Insa M Schmidt; Gilbert W Moeckel; Rachel J David; Richard A Flavell; Peter S Aronson
Journal:  Kidney Int       Date:  2013-06-05       Impact factor: 10.612
View more
  3 in total

Review 1.  Recent advances in the identification and management of inherited hyperoxalurias.

Authors:  David J Sas; Peter C Harris; Dawn S Milliner
Journal:  Urolithiasis       Date:  2018-12-10       Impact factor: 3.436

2.  Transferrin-Dressed Virus-like Ternary Nanoparticles with Aggregation-Induced Emission for Targeted Delivery and Rapid Cytosolic Release of siRNA.

Authors:  Tingbin Zhang; Weisheng Guo; Chunqiu Zhang; Jing Yu; Jing Xu; Shuyi Li; Jian-Hua Tian; Paul C Wang; Jin-Feng Xing; Xing-Jie Liang
Journal:  ACS Appl Mater Interfaces       Date:  2017-05-03       Impact factor: 9.229

3.  Recovery From Dialysis in Patients With Primary Hyperoxaluria Type 1 Treated With Pyridoxine: A Report of 3 Cases.

Authors:  Elizabeth C Lorenz; John C Lieske; Barbara M Seide; Julie B Olson; Ramila Mehta; Dawn S Milliner
Journal:  Am J Kidney Dis       Date:  2020-09-04       Impact factor: 8.860
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.